3D Epigenome in Cancer Group

Central to this is understanding the role of epigenome and 3D genome alterations in driving cancer development, progression and treatment resistance, with a focus on breast and prostate cancer. For that, we combine and integrate cutting-edge genomics technology, single-cell epigenome profiling, genome editing and pre-clinical models to study the interplay of the 3D genome and epigenome in cancer.

The group has key interest in developing new epigenomic and single-cell technologies, including ongoing optimisation of chromosome conformation capture-based methods (Hi-C, Capture Hi-C, HiChIP) and bioinformatics for 3D genome structure mapping and the development of high-throughput single-cell and spatial 3D genome and epigenome profiling techniques.